{
 "name": "逸達",
 "slug": "tw-6576",
 "aliases": [
  "逸達生物科技股份有限公司",
  "Foresee",
  "6576"
 ],
 "ticker": "6576",
 "industry": "生技醫療業",
 "website": "www.foreseepharma.com",
 "summary": "逸達（6576）是上櫃的生技醫療類股公司，2013 年成立，2018 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "逸達生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "Foresee",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2018-06-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2013-02-08",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "簡銘達",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "簡銘達",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 1575405410,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "www.foreseepharma.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 6271,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -1.09,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -14.2,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "管線：FP-001 42 mg（CAMCEVI／leuprolide mesylate）",
   "value": "成人晚期前列腺癌｜已獲 NMPA 上市核准｜中國",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china"
  },
  {
   "claim": "管線：FP-001 21 mg（CAMCEVI ETM／leuprolide mesylate）",
   "value": "前列腺癌｜已獲上市核准｜美國、加拿大、歐盟、英國",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china"
  },
  {
   "claim": "管線：FP-001 42 mg（CAMCEVI／leuprolide mesylate）",
   "value": "停經前乳癌｜第三期試驗完成；新增適應症申請已獲 NMPA 受理實質審查｜中國",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china"
  },
  {
   "claim": "管線：FP-001 42 mg（leuprolide mesylate）",
   "value": "兒童中樞性性早熟｜III 期（已完成）｜中國、波多黎各、台灣、美國",
   "unit": "",
   "as_of": "2026-07-20",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05493709",
   "note": "NCT 編號：NCT05493709；as_of 為登錄最後更新公開日。"
  },
  {
   "claim": "管線：FP-025（aderamastat）",
   "value": "輕度嗜酸性塵蟎過敏氣喘｜II 期（已完成）｜荷蘭",
   "unit": "",
   "as_of": "2024-05-30",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03858686",
   "note": "NCT 編號：NCT03858686；as_of 為登錄最後更新公開日。此為完成之II期概念驗證試驗；後續MMP-12計畫已全球授權Primevera。"
  },
  {
   "claim": "管線：FP-020（linvemastat）",
   "value": "控制不完全之氣喘｜II 期（尚未收案）｜地區未公開",
   "unit": "",
   "as_of": "2026-07-20",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07191535",
   "note": "NCT 編號：NCT07191535；as_of 為登錄最後更新公開日。登錄未列試驗地點；不推定地區。後續開發由Primevera負責。"
  },
  {
   "claim": "管線：FP-045（mirivadelgat）",
   "value": "間質性肺病相關肺高壓（PH-ILD）｜II 期（收案中）｜波士尼亞與赫塞哥維納、台灣",
   "unit": "",
   "as_of": "2026-09-21",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06475781",
   "note": "NCT 編號：NCT06475781；as_of 為登錄最後更新公開日。"
  },
  {
   "claim": "管線：FP-014 22.5 mg（triptorelin mesylate）",
   "value": "晚期前列腺癌｜III 期（已撤回）｜地區未公開",
   "unit": "",
   "as_of": "2025-04-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06795191",
   "note": "NCT 編號：NCT06795191；as_of 為登錄最後更新公開日。WITHDRAWN登錄，不將原估完成日列為催化劑，也不推定整個FP-014計畫停止。"
  },
  {
   "claim": "管線：FP-014 11.25 mg（triptorelin mesylate）",
   "value": "晚期前列腺癌｜III 期（已撤回）｜地區未公開",
   "unit": "",
   "as_of": "2025-04-27",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06795178",
   "note": "NCT 編號：NCT06795178；as_of 為登錄最後更新公開日。WITHDRAWN登錄，不將原估完成日列為催化劑，也不推定整個FP-014計畫停止。"
  },
  {
   "claim": "簽約金：MMP-12抑制劑組合（FP-025、FP-020及第三代候選物）",
   "value": 10000000,
   "unit": "美元",
   "as_of": "2026-01-08",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc",
   "note": "逸達美國子公司收取之組合交易簽約金；本項不表示已入帳。 對象為Primevera Therapeutics LLC，MMP-12組合全球授權；精確簽字日未明，不以2026-01-08公告日充作簽約日。"
  },
  {
   "claim": "已收金額（公告日為準）：MMP-12抑制劑組合（FP-025、FP-020及第三代候選物）",
   "value": 10000000,
   "unit": "美元",
   "as_of": "2026-05-19",
   "source": "https://mopsov.twse.com.tw/nas/STR/657620260519E001.pdf",
   "note": "限本簡報明確稱已收到的簽約金；非整個交易已收總額，不含未發生里程碑。 對象為Primevera Therapeutics LLC，MMP-12組合全球授權；精確簽字日未明，不以2026-01-08公告日充作簽約日。"
  },
  {
   "claim": "權利金比率：MMP-12抑制劑組合（FP-025、FP-020及第三代候選物）",
   "value": "個位數階梯式百分比（未公開精確比率）",
   "unit": "%",
   "as_of": "2026-01-08",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc",
   "note": "原文為 tiered single-digit percentage royalties；不得轉成特定數字；若Primevera再授權，改依公告所述再授權收益分成安排。 對象為Primevera Therapeutics LLC，MMP-12組合全球授權；精確簽字日未明，不以2026-01-08公告日充作簽約日。"
  },
  {
   "claim": "簽約金：FP-001（GenSci中國交易）",
   "value": 8000000,
   "unit": "美元",
   "as_of": "2020-11-17",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_enters_exclusive_license_agreement_with_gensci_for_the_commercialization_of_camcevi_in_china",
   "note": "公告will receive；未據此當成已收金額。"
  },
  {
   "claim": "簽約金：FP-001（Intas美國交易）",
   "value": 10000000,
   "unit": "美元",
   "as_of": "2021-03-04",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_enters_exclusive_license_agreement_with_intas_pharmaceuticals_for_commercialization_in_the_united_states",
   "note": "公告will receive；未據此當成已收金額。"
  },
  {
   "claim": "催化劑：FP-001 42 mg",
   "value": "兒童中樞性性早熟適應症向美國 FDA 提交 NDA｜2026下半年（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china",
   "note": "非已送件證據。"
  },
  {
   "claim": "催化劑：FP-016",
   "value": "進入人體臨床試驗｜2027年底（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china"
  },
  {
   "claim": "催化劑：FP-018",
   "value": "進入人體臨床試驗｜2027年底（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china"
  },
  {
   "claim": "催化劑：FP-001 21 mg",
   "value": "CAMCEVI 3個月劑型於美國上市｜2026-Q4（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-19",
   "source": "https://mopsov.twse.com.tw/nas/STR/657620260519E001.pdf"
  },
  {
   "claim": "催化劑：FP-001 21 mg",
   "value": "CAMCEVI 3個月劑型於加拿大上市｜2027-Q1（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-19",
   "source": "https://mopsov.twse.com.tw/nas/STR/657620260519E001.pdf"
  },
  {
   "claim": "催化劑：FP-001 42 mg",
   "value": "CAMCEVI 6個月劑型於中國上市｜2027上半年（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-19",
   "source": "https://mopsov.twse.com.tw/nas/STR/657620260519E001.pdf",
   "note": "2026-10-12已公告中國上市核准；此筆只記原公開上市時程，未聲稱已開始銷售。"
  },
  {
   "claim": "催化劑：FP-045",
   "value": "WINDWARD II期試驗期中分析｜2027-Q3前（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-05-19",
   "source": "https://mopsov.twse.com.tw/nas/STR/657620260519E001.pdf",
   "note": "NCT 編號：NCT06475781；不同於整體試驗主要完成日。"
  },
  {
   "claim": "催化劑：FP-045",
   "value": "試驗登錄預估主要完成日｜2028-02（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-09-21",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06475781",
   "note": "NCT 編號：NCT06475781；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "催化劑：FP-020",
   "value": "試驗登錄預估主要完成日｜2028-01-01（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-07-20",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07191535",
   "note": "NCT 編號：NCT07191535；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "里程碑金上限：MMP-12抑制劑組合（FP-025、FP-020及第三代候選物）",
   "value": 574500000,
   "unit": "美元",
   "as_of": "2026-01-08",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc",
   "note": "2026-01-08正式簽署公告正文明列future potential milestones up to 574.5 million USD；同頁摘要寫584.5 million，兩處不一致，保留差異。MOPS發言日期2025-12-30 18:35:39、6576/114年度序號1，主旨：(補充公告) 本公司董事會決議通過將MMP-12抑制劑授權予關係人，亦明列後續最高5億7,450萬美元。採最終簽署正文與官方重訊相同之574.5m，未自行用總額相減；是未來條件式里程碑上限，非已收金額。MOPS查詢頁：https://mops.twse.com.tw/mops/#/web/t05st01。"
  },
  {
   "claim": "管線：FP-001 42 mg（CAMCEVI／leuprolide mesylate）",
   "value": "成人晚期前列腺癌｜已獲上市核准｜美國、加拿大、歐盟、台灣、以色列、英國",
   "unit": "",
   "as_of": "2026-10-12",
   "source": "https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_china_nmpa_approval_of_camcevi__42_mg_for_the_treatment_of_advanced_prostate_cancer__changchun_genescience_pharmaceutical_will_commercialize_in_china",
   "note": "官網About CAMCEVI及About Foresee明列42mg已核准地區；各國標籤可能不同，應以當地核准仿單為準。此筆記上市核准，未主張所有地區均已開始銷售；美國於2022年4月上市的歷史與本筆核准範圍分開。中國當日核准另列一筆，不在此重複。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6576.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}